NFL Biosciences S.A.
ALNFL.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €19,366 | €11,674 | €10,286 | €12,563 |
| - Cash | €1,914 | €2,338 | €1,054 | €3,040 |
| + Debt | €41 | €62 | €83 | €85 |
| Enterprise Value | €17,493 | €9,398 | €9,316 | €9,609 |
| Revenue | €0 | €200 | €0 | €0 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | -€67 | -€56 | -€2,236 | -€531 |
| % Margin | -145,963% | -28% | – | -1,360,853.8% |
| EBITDA | -€2,649 | -€4,049 | -€2,808 | -€1,075 |
| % Margin | -5,758,256.5% | -2,024.5% | – | -2,757,612.8% |
| Net Income | -€2,081 | -€3,745 | -€2,443 | -€978 |
| % Margin | -4,523,563% | -1,872.6% | – | -2,508,317.9% |
| EPS Diluted | -0.21 | -0.46 | -0.47 | -0.19 |
| % Growth | 54.3% | 2.1% | -147.4% | – |
| Operating Cash Flow | €0 | €0 | €105 | €87 |
| Capital Expenditures | €0 | €0 | €0 | €0 |
| Free Cash Flow | €0 | €0 | €105 | €87 |